metastatic colorectal cancer epidemiology forecast insight

DelveInsight’s ‘Metastatic Colorectal Cancer (mCRC) - Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Metastatic Colorectal Cancer (mCRC) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Metastatic Colorectal Cancer (mCRC) Understanding

Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped together because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.

CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer is the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC.

Generally, most CRCs (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one’s children. Inherited CRCs are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of CRC is not known.

Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is.

If cancer forms in a polyp, it can grow into the wall of the colon or rectum over time. The wall of the colon and rectum is made up of many layers. CRC starts in the innermost layer (the mucosa) and can grow outward through some or all of the other layers. When cancer cells are in the wall, they can then grow into blood vessels or lymph vessels (tiny channels that carry away waste and fluid). From there, they can travel to nearby lymph nodes or distant parts of the body. The stage (extent of spread) of a CRC depends on how deeply it grows into the wall and if it has spread outside the colon or rectum.

Metastatic Colorectal Cancer (mCRC) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by  Total Incident Population of Colorectal Cancer, and Total Incident Population of Metastatic Colorectal Cancer (mCRC) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2021 to 2034.

Metastatic Colorectal Cancer (mCRC) Detailed Epidemiology Segmentation

• The incident population of CRC in the seven major markets was 532,433 in 2020.
• In the 7MM, the highest number of incident cases of Colorectal Cancer was observed in the US, with 146,589 cases in the year 2020.
• In the year 2020, the total incident cases of metastatic colorectal cancer were 207,873 cases in the 7MM.
• In the EU-5 countries the incident cases of metastatic colorectal cancer were 92,889 cases in the year 2020, with highest cases being reported in Germany.

Scope of the Report

• The report covers the descriptive overview of Metastatic Colorectal Cancer (mCRC), explaining its causes, signs and symptoms, pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Metastatic Colorectal Cancer (mCRC).
• The report provides the segmentation of the disease epidemiology for the 7MM by Total Incident Population of Colorectal Cancer, and Total Incident Population of Metastatic Colorectal Cancer (mCRC).

Report Highlights

• Ten Year Forecast of Metastatic Colorectal Cancer (mCRC)
• 7MM Coverage

Key Questions Answered

• What is the disease risk, burden and unmet needs of Metastatic Colorectal Cancer (mCRC)?
• What is the historical Colorectal Cancer (CRC) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What is the historical Metastatic Colorectal Cancer (mCRC) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Metastatic Colorectal Cancer (mCRC) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Metastatic Colorectal Cancer (mCRC)?
• Out of the above-mentioned countries, which country would have the highest incident population of Metastatic Colorectal Cancer (mCRC)during the forecast period (2025-2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2025-2034)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Metastatic Colorectal Cancer (mCRC).
• To understand the future market competition in the Metastatic Colorectal Cancer (mCRC) market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Metastatic Colorectal Cancer (mCRC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Metastatic Colorectal Cancer (mCRC) market.
• To understand the future market competition in the Metastatic Colorectal Cancer (mCRC) market.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population